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Abstract
Background: Pharmacists in Japan currently play a key role in patient hospital care. Their responsibilities include
filling prescriptions, checking a patient’s medication history, and providing appropriate information to other health
care workers. More importantly, pharmacists’ interventions can also result in reductions in adverse drug reactions
(ADRs) and, ultimately, in cost savings. This study aimed to determine the economic value of such interventions at
a hospital in Japan.
Methods: At a single Japanese hospital, we analyzed 1452 pharmaceutical interventions by pharmacists, including
recommending antibiotic dosage regimens, attending ward rounds with multidisciplinary health providers,
providing drug information, and reporting ADRs. We classified the interventions into 13 categories. Using data from
the PreAVOID Report by the Japanese Society of Hospital Pharmacists, along with previous studies, we estimated
the cost savings of the interventions.
Results: Various savings could be realized through appropriate interventions by hospital pharmacists. Based on the
amount paid by the Pharmaceuticals and Medical Devices Agency, we calculated the cost savings associated with
preventing serious ADRs as 21,400 USD ($) per case. The cost savings for recommendations related to transvenous
antimicrobial therapy amounted to $1900 per patient. Pharmacists’ interventions were able to prevent 12 cases of
serious ADRs.
Conclusions: Determining the economic value of pharmacists’ interventions is an important means of appraising
the current role of hospital pharmacists. Our evaluation demonstrates the positive economic effects of pharmacists’
interventions in a hospital setting.
Background
Pharmacists today play a greater role in providing phar-
macotherapeutics to patients [1]. However, to date, the
economic contribution of various pharmaceutical inter-
ventions in a medical setting has not been thoroughly
investigated in Japan. In this study, we calculated the eco-
nomic impact of pharmaceutical interventions, including
multidisciplinary teamwork, using an evidence-based
approach.
It has been reported that in the United States of
America, 6.7 % of the adverse effects resulting from
pharmaceuticals administered to hospitalized patients
are considered serious, and 0.32 % are fatal [2]. Similar
figures have also appeared in a recent review [3].
Another US study has shown that patients who experi-
ence adverse effects have longer hospital stays and
higher mortality rates than those who do not [4]. In
addition, some studies have demonstrated that medical
costs from pharmaceutical adverse effects are increasing
annually [5, 6]. In 2011 in Japan, 959 cases of adverse
drug reactions (ADRs) were referred to the ADR relief
services of the Pharmaceuticals and Medical Devices
Agency (PMDA). Those ADRs cost the PMDA
$20,583,890 [7]. In Japan, the PMDA provides a medical
allowance for harm to health that results from incorrect
use of drugs (e.g., diseases and disabilities requiring
hospitalization caused by adverse effects of drugs at
hospitals and clinics).* Correspondence: akiki@m.ehime-u.ac.jp
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The most important role of a pharmacist is to ensure ef-
fective, safe drug therapy for the patient. In preventing
drug-related adverse events, the hospital pharmacist acts
as a risk manager for hospitalized patients. Furthermore,
the pharmaceutical evidence-based interventions of phar-
macists play a useful role in medical treatment [8, 9]. A
ward-based pharmaceutical service was introduced as a
medical treatment bonus after fiscal 2012 in Japan; since
then, the role of the pharmacist in hospital wards has
expanded. Pharmacists have a number of responsibilities
on the ward, including filling prescriptions, monitoring
patients’ drug histories, avoiding drug interactions, provid-
ing drug information to medical staff, and recommending
drug regimens. Pharmacists now also perform a pharma-
ceutical service for outpatients receiving chemotherapy. It
has been reported that $565,664 per year could be saved
by avoiding serious ADRs through continuous pharma-
ceutical interventions by pharmacists in US emergency
care [10]. In addition, Niwa reported that a savings of
301,290,758 JPY ($3,012,907) per year per patient could be
achieved by establishing a program to ensure the appro-
priate use of antimicrobial drugs in Japanese hospitals
[11]. To date, however, no study has examined the eco-
nomic impact of individual pharmaceutical interventions
by pharmacists in Japan; therefore, this was the goal of the
present study.
Methods
The study was carried out in accordance with the guide-
lines for the care for human study adopted by the Ethics
Committee of Ehime University Hospital (Ehime, Japan;
approval number 1408004 of the review board). This
investigation focuses on a single hospital and is a retro-
spective report of pharmacy interventions at Ehime
University Hospital. Therefore, we did not obtain written
informed consent for study participation. As of March
2014, the hospital had 626 beds and 41 pharmacists. We
analyzed pharmacy interventions, including recommend-
ing antibiotic dosage regimens, attending ward rounds
with multidisciplinary health providers, providing drug
information, and reporting ADRs. We examined a total
of 1452 pharmaceutical interventions performed at
Ehime University Hospital from April 2013 to March
2014. We recorded and stored interventions in a web-
based severity reaction database built by the Japanese
Society of Hospital Pharmacists (JSHP) [12]. We catego-
rized the 1452 reports into 13 types, following the classi-
fication used in Hamblin et al. [10]: (1) avoidance of
serious ADRs; (2) transvenous antimicrobial therapy
interventions; (3) switch from intravenous to oral
administration; (4) interventions concerning cancer
chemotherapy; (5) avoidance of drug interactions; (6)
renal dosing recommendations; (7) intravenous drug
compatibility; (8) confirmation of medication history
(presurgical cessation of antiplatelet drugs); (9) drug
therapy consultation or recommendations; (10) monitor-
ing recommendations; (11) ward rounds, multidisciplin-
ary teamwork; (12) drug information; and (13) ADRs
reported to the PMDA.
In view of the cost of ADRs to the PMDA, we estimated
that there could be an average saving of $21,400 through
the avoidance of serious ADRs in Japan: $20,583,890 (1
USD = 100 JPY)/959 = $21,464). In this study, we defined
serious ADRs as serious adverse effects described in the
printed information inserts in the drug packaging. We
determined the cost savings with recommendations for
transvenous antimicrobial therapy—the dosage regimen of
anti-methicillin-resistant Staphylococcus aureus (MRSA)
drugs—with reference to the study by Niwa [11]. That re-
port stated that daily savings of $272.37 per patient could
be realized using the recommendations for transvenous
antimicrobial therapy. At the hospital in the present study,
anti-MRSA drugs are administered for an average of
7 days. Therefore, approximately $1900 per patient could
be saved by appropriate pharmaceutical interventions
($272.37 × 7 = $1906.59). With regard to the switch from
intravenous to oral administration, we calculated the cost
difference per day multiplied by the number of days of
oral administration.
Hamblin et al. reported that 2.6–5.21 % of pharma-
ceutical interventions, e.g., avoidance of drug interac-
tions and attention to renal dosing recommendations,
lead to the avoidance of serious ADRs [10]. We defined
the economic contributions of individual pharmaceutical
interventions based on Hamblin et al. and described the
rate at which routine interventions could prevent serious
ADRs (2.6–5.21 %). Adverse effects can occur with any
drug, but such effects are particularly common with an-
ticancer agents, and these drugs also represent the high-
est risk from the standpoint of reaction severity.
Therefore, according to the risk of expression of
ADRs, we classified previously described pharmaceut-
ical interventions (4) to (9) into three categories:
interventions for cancer chemotherapy, high-risk
drugs exclude anticancer agents, and others. We de-
fined the economic contribution for each pharmaceut-
ical intervention. For interventions related to cancer
chemotherapy, the contribution was approximately
$1120 ($21,400 × 5.21 % = $1118.27). The contribution
for high-risk drugs was about $840 ($21,400 × 3.91 %
[the intermediate value between 2.6 % and 5.21 %]
= $839.24). The contribution for others amounted to
about $560 ($21,400 × 2.6 % = $558.06). In this study,
we defined high-risk drugs according to JSHP busi-
ness guidelines for these drugs [12]. Furthermore,
based on the Hamblin et al. report [10], the medical
economic contributions of pharmaceutical interven-
tions (10) to (13) were defined as $0 (Table 1).
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Results
Table 2 shows the results of the classified pharmaceut-
ical interventions. We grouped the 1452 interventions
into the 13 categories described above. There were 640
instances of drug information, e.g., information given to
doctors, pharmacists, nurses, or other health profes-
sionals. We estimated the medical economic contribu-
tion from these pharmaceutical interventions to be
$876,017.
There were 12 instances of avoidance of serious ADRs,
for which the savings were $256,800 (Table 3). Chemo-
therapy accounted for seven cases and avoidance of
renal failure for two cases. There were 172 cases of
transvenous antimicrobial therapy interventions, primar-
ily involving Therapeutic Drug Monitoring: 121 of
vancomycin (VCM); 37 of teicoplanin (TEIC); six of
patients who switched to TEIC from VCM or vice versa;
one of linezolid (LZD) one of arbekacin (ABK); and six
of others. Total savings were $325,080. Regarding the
change from intravenous to oral administration, vorico-
nazole (VRCZ) featured twice and LZD four times. The
administration period of the oral antimicrobial was
55 days for VRCZ and 32 days for LZD.
Figure 1 shows the interventions for cancer chemo-
therapy. There were 48 interventions for supportive
therapy recommendations, 16 for checking prepared
drugs, 12 for dosing recommendations, and six other
interventions, with total savings of $91,840. The inter-
ventions mainly involved suggestions of appropriate an-
tiemetic drugs and avoidance of serious ADRs.
Table 4 presents the cases of avoidance of drug inter-
actions, which represented savings of $33,040. Three
interventions involved contraindications for coadminis-
tration, and 55 concerned a combination of issues. Most
drug interactions were related to absorption inhibition.
There were 50 cases of renal dosing recommendations:
for the main drugs famotidine, allopurinol, and levoflox-
acin, there were 12, 8, and six interventions, respectively,
with combined savings of $29,960. Pharmacists were
able to contribute to preventing renal function aggrava-
tion and various adverse effects, such as hypoglycemia,
by decreasing the dosage of oral antidiabetic medication
and changing to an agent other than loxoprofen sodium
for patients with reduced renal function.
There were three cases involving intravenous drug
compatibility, for the drugs heparin and fat emulsion,
iron oxide and normal saline, and VCM and micafungin;
the savings were $1960.
Regarding drug therapy consultation or recommenda-
tions, there were 50 cases of discontinuing unnecessary
drugs, 36 for the prevention of ADRs (except cancer
chemotherapy), and 12 for sleep control, with savings of
$112,000. A further eight interventions were recorded
for pain control, 15 for bowel motion control, and 18 for
the correction of prescription errors. There were seven
cases of contraindication, three for avoiding inefficient
drug therapy, and 34 for other interventions according
to the patient’s condition (Fig. 2). Active pharmaceutical
interventions depended on the state of the patient; for
example, pain control and bowel motion control were
commonly implemented interventions.
In all, 463 interventions concerned additional drugs.
In 122 (26.3 %) cases, the dosage was decreased; there
were 82 cases (17.7 %) of drug discontinuation and 78
Table 1 Classification of pharmaceutical interventions and cost savings
Intervention type Cost savings
1. Avoidance of serious ADRs Benefits paid by PMDA to sufferers of ADRs in 2013: USD $20,583,890
Number of incidents: 959
Average amount: $21,464
i.e., $21,400/case
2. Transvenous antimicrobial therapy interventions $272.37/patient/day × 7 daysa = $1906.59/patient, i.e., $1900/patient
3. Switch from intravenous to oral administration Difference in cost between intravenous and oral administration per day × days of
oral administration
4. Interventions concerning cancer chemotherapy
5. Avoidance of drug interactions
6. Renal dosing recommendations
7. Intravenous drug compatibility
8. Confirmation of medication history (presurgical cessation of
antiplatelet drugs)
9. Drug therapy consultation or recommendations
Likelihood that a general intervention leads to preventing an ADR ranges from
2.6 to 5.21 %
Most risky drug therapy: cancer chemotherapy
$21,464 × 5.21 % = $1118.27, i.e., $1120/case
Intermediate risky drug therapy: high-risk drugs defined by JSHP
$21,464 × 3.91 % = $839.24, i.e., $840/case
Normal drug therapy: others
$21,464 × 2.60 % = $558.06, i.e., $560/case
10. Monitoring recommendations
11. Ward rounds, multidisciplinary teamwork
12. Drug information
13. ADRs reported to PMDA
These types are not directly reflected in the cost estimation, i.e., $0
aThe average number of days that anti-MRSA drugs were used at the study hospital
Multiple interventions for a single patient were counted as one intervention
ADR serious adverse drug reaction, PMDA Pharmaceuticals and Medical Devices Agency, JSHP Japanese Society of Hospital Pharmacists
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Table 2 Estimation of annual economic impact





1 Avoidance of serious ADRs 12 21,400 256,800 Quality/safety
improved
2 Transvenous antimicrobial therapy interventions 172 1900 325,080 Pharmacotherapy
improved
3 Switch from intravenous to oral administration Voriconazole 55 165.1 9078 Cost saving
Linezolid 32 96.9 3099
4 Interventions concerning cancer chemotherapy 82 1120 91,840 Pharmacotherapy
improved
5 Avoidance of drug interactions High risk 2 840 1680 Pharmacotherapy
improved
Normal 56 560 31,360
6 Renal dosing recommendations High risk 7 840 5880 Pharmacotherapy
improved
Normal 43 560 24,080
7 Intravenous drug compatibility High risk 1 840 840 Pharmacotherapy
improved
Normal 2 560 1120
8 Confirmation of medication history (presurgical cessation of
antiplatelet drugs)
High risk 13 840 10,920 Quality/safety
improved
Normal 4 560 2240
9 Drug therapy consultation or recommendations High risk 34 840 285,60 Pharmacotherapy
improved
Normal 149 560 834,40
10 Monitoring recommendations 19 0 0 Pharmacotherapy
improved
11 Ward rounds, multidisciplinary teamwork ICT 28 0 0 Quality/safety
improved
NST 45 0 0
PCT 52 0 0
12 Drug information 640 0 0 Provider education
13 ADRs reported to PMDA 4 0 0 Quality/safety
improved
Total 1452 - 876,017
ADRs serious adverse drug reactions, ICT infection control team, NST nutrition support team, PCT pain control team, PMDA Pharmaceutical and Medical
Devices Agency
Table 3 Avoidance of serious adverse drug reactions
No. Case Pharmaceutical intervention
1 Renal function worsening due to a combination of fibrates and statins Discontinue fibrates
2 Lithium intoxication and acute renal failure in patients orally administered
lithium carbonate
Measure blood lithium concentration and discontinue lithium
carbonate
3 Liver dysfunction because of phenytoin Change to other anti-epileptic drugs
4 Hypoglycemia with oral diabetes drugs Reduce dose of oral diabetes drugs
5 Pancytopenia after an increase in carbamazepine dosage Discontinue carbamazepine
6 Bevacizumab administered to a patient with planned tooth extraction Change to chemotherapy without bevacizumab
7 Start of chemotherapy for grade 4 neutropenic patients Postpone chemotherapy
8 No blood test after chemotherapy (grade 4 neutropenia) Recommend blood test
9 Onset of grade 2 peripheral neuropathy after chemotherapy Begin adjuvant analgesics
10 Anaphylaxis by premedication at start of chemotherapy Change premedication
11 Start of chemotherapy for patients untreated for HBV-DNA-positive conversion Postpone chemotherapy and begin oral administration of
entecavir
12 Start of chemotherapy for patients untreated for HBV-DNA detection Begin oral administration of entecavir
HBV Hepatitis B virus
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cases (16.8 %) of the drugs’ being changed; 57 (12.3 %)
cases represented a change in the dose regimen and 50
cases (10.8 %) other interventions (Fig. 3). All the
interventions regarding monitoring recommendations
included the recommendation for hepatitis B screening.
Discussion
One study has reported that pharmaceutical inquiries
regarding prescriptions by community pharmacists were
effective from a medical economic perspective, repre-
senting savings of $11,888 [13]. In the present investiga-
tion, we conducted an economic evaluation of the effect
of individual pharmaceutical interventions by clinical
pharmacists. It is generally considered necessary to
calculate costs induced by the adverse effects of drugs.
However, it is very difficult to determine such costs, due
to the great variety of drugs and their adverse effects. In
this study, the individual outcomes in the absence of in-
terventions were unknown. Therefore, we could not as-
sess the expected economic contribution when an ADRs
occurred because medical expenses vary greatly.
The damage relief system for ADRs offered by Japan’s
PMDA involves compensation contingent on appropri-
ate use of the pharmaceuticals. We calculated the
average compensation paid to a patient in Japan after a
serious adverse effect at $21,400, which is $6000 higher
than the figure reported by Hamblin et al. [10] One rea-
son for the high cost of PMDA compensation is that it
includes a patient benefit (The PMDA is an incorporated
administrative agency under the Ministry of Health,
Labour and Welfare, and we therefore considered it
appropriate to include that benefit when calculating the
economic contributions).
Our analysis of 1452 pharmaceutical interventions
indicated that serious ADRs were avoided in 12 cases.
This underlines the importance of the pharmacist in
ward drug duties to ensure the safe management of
patient medical treatment. In transvenous antimicrobial
therapy interventions, most cases involved VCM, TEIC,
and ABK. Approximately 70 % of interventions con-
cerned VCM cases. VCM is recommended as a first-line
drug in MRSA infectious disease treatment guidelines in
Japan. Switch therapy constitutes a change in adminis-
tration of antimicrobial drugs from an intravenous drip
to oral medication. It has been shown that switch ther-
apy can reduce both medical expenses and length of
hospital stay if introduced at an early stage of treatment
[14]. From a cost perspective and because of their high
bioavailability, we considered VRCZ and LZD to be
suitable for switch therapy. With switch therapy, we esti-
mated the cost savings at approximately $12,000 due to
cost differences in the drugs.
The most common intervention for cancer chemother-
apy involved recommendations for supportive therapy.
Therefore, we believe that pharmacists can prevent or
Fig. 1 Interventions for cancer chemotherapy
Table 4 Avoidance of drug interactions
Contraindication for coadministration Number
Azathioprine Febuxostat 1
Atorvastatin Bezafibrate 1
Ferrous citrate Albumin tannate 1
Combination of issues Number
Magnesium oxide Cefdinir 13
Magnesium oxide Oral new quinolone 13
Oral iron supplement Cefdinir 9
Oral iron supplement Levofloxacin 6





Polystyrene sulfonate calcium Magnesium oxide 1
Cefdinir Sucralfate 1
SM powder Levofloxacin 1
Total 58
SM Sankyo Magen Mittel
Oral iron supplement: ferrous citrate, ferrous fumarate, soluble
ferric pyrophosphate
Antimicrobial: ampicillin/sulbactam, levofloxacin, erythromycin
Oral new quinolone: levofloxacin, minomycin, ciprofloxacin
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relieve the frequent onset of serious adverse effects of an
anticancer agent by suggesting supportive therapy.
Cancer chemotherapy often causes critical adverse
effects. Accordingly, we assumed the rate of serious
ADRs to be 5.21 %.
Contraindications for coadministration were extracted
by the computer system and printed on prescriptions, so
such risks were basically averted in our hospital. Because
cases that involve only a prescription do not qualify as
interventions in this study, only three cases of actual
interventions occurred in this category.
Intravenous drug incompatibility not only reduces the
titer of the drug, but also may cause a side effect.
Because various infusions may be mixed in this route of
administration, a careful chemical judgment is required.
Only three cases occurred in this study, but ensuring com-
patibility is an important pharmaceutical intervention.
Regarding the confirmation of medication history,
pharmacists commonly intervened in the discontinu-
ation of preoperative anticoagulants and their postopera-
tive readministration. For example, with angiotensin II
receptor antagonists and angiotensin-converting enzyme
inhibitors, it is recommended that the pharmacist cancel
such prescriptions before an operation under practice
guidelines for surgical medical care [15]. Similarly, many
other drugs and anticoagulants should be discontinued
before an operation. We would argue that such pharma-
cist interventions lead to the avoidance of adverse events
during an operation and indicate a pharmacist’s appro-
priate assessment of drug use in hospitals.
Pharmacists need to target their efforts particularly to-
ward improving medication safety to prevent ADRs. Pa-
tients who experience an ADR require a longer hospital
stay, which results in greater hospital costs [5, 16]. Any
intervention that reduces ADRs will have a significant
impact on patient care and health care costs. Drug costs
can be directly increased or decreased by adding or re-
moving a drug prescription. However, since the present
study focuses on the economic contribution related to
the prevention of adverse effect, we have not included
the costs associated with adding or removing drugs.
There are four intervention types (Monitoring recom-
mendations, Ward rounds, multidisciplinary teamwork,
Drug information, ADRs reported to PMDA) for which
we did not estimate economic effects in this study. Co-
operation among medical care team members is known
Fig. 2 Drug therapy consultations or recommendations
Fig. 3 Method of intervention
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to be a strong contributor to symptom relaxation and
improvement of the patient’s QOL [17]. Regarding ward
rounds and multidisciplinary teamwork, there were 28
cases of infection control team, 45 cases of nutrition
support team, and 52 cases of pain control team. The
intervention category of drug information, including
education of ward staff, contained 640 cases. These
interventions therefore offer many opportunities for
economic contributions.
Lazarou et al. [2] found that 50 % of the adverse
effects of pharmaceutical products were preventable [2].
Bond and Raehl [4] estimated that $30 billion a year
could be saved by avoiding adverse effects—even if such
effects were preventable in only approximately 50 % of
hospitals in the USA [4] (just a small number of hospi-
tals are registered with the US adverse effect-reporting
system). In Japan, the proportion of medical expenses
attributed to ADRs is unknown. The present study is the
first to investigate medical-related economic contribu-
tions in Japan, and we therefore believe that it
contributes to the avoidance of adverse effects.
Conclusions
In this study, we conducted medical-related economic
evaluations using an original estimation system. We
calculated the effects of individual pharmaceutical inter-
ventions by pharmacists on reducing medical costs. In
this way, we were able to determine the economic
contributions of such interventions. Other pharmacists
can use this work to evaluate interventions economic-
ally, using our classification and estimation system.
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